<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               2  DOSAGE AND ADMINISTRATION<BR>               <BR>               <BR>                  <BR>                     <BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="70%"><BR>                           <col width="80%" align="left" valign="top"/><BR>                           <col width="20%" align="left" valign="top"/><BR>                           <tbody><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">When given with potent CYP3A inhibitors (with or without potent CYP3A inducers) including PIs (except tipranavir/ritonavir), delavirdine (<linkHtml href="#S2">2</linkHtml>, <linkHtml href="#S7.1">7.1</linkHtml>)</td><BR>                                 <td styleCode="Rrule">150 mg twice daily</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">With NRTIs, tipranavir/ritonavir, nevirapine, raltegravir, and other drugs that are not potent CYP3A inhibitors or CYP3A inducers (<linkHtml href="#S2">2</linkHtml>, <linkHtml href="#S7.1">7.1</linkHtml>)</td><BR>                                 <td styleCode="Rrule">300 mg twice daily</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">With potent CYP3A inducers including efavirenz (without a potent CYP3A inhibitor) (<linkHtml href="#S2">2</linkHtml>, <linkHtml href="#S7.1">7.1</linkHtml>)</td><BR>                                 <td styleCode="Rrule">600 mg twice daily</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>A more complete list of coadministered drugs is listed in Dosage and Administration (2).<BR>                        <BR>                        Dose adjustment may be necessary in patients with renal impairment. (2.2).<BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     2.1  Dose Recommendations for Patients with Normal Renal Function <BR>                     <BR>                        The recommended dose of SELZENTRY differs based on concomitant medications due to drug interactions (see Table 1). SELZENTRY can be taken with or without food. SELZENTRY must be given in combination with other antiretroviral medications. <BR>                        Table 1 gives the recommended dose adjustments [see Drug Interactions (7.1)<BR>                           ]. <BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="100%" ID="table1"><BR>                           <caption>Table 1 Recommended Dosing Regimen</caption><BR>                           <col width="70%" align="left" valign="top"/><BR>                           <col width="30%" align="center" valign="middle"/><BR>                           <thead><BR>                              <tr><BR>                                 <th styleCode="Lrule Rrule" align="center">Concomitant Medications</th><BR>                                 <th styleCode="Rrule">SELZENTRY Dose</th><BR>                              </tr><BR>                           </thead><BR>                           <tbody><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule"><BR>                                    <br/> Potent CYP3A inhibitors (with or without  a potent CYP3A inducer) including:<list listType="unordered" styleCode="Disc"><BR>                                       <item>protease inhibitors (except tipranavir/ritonavir) </item><BR>                                       <item>delavirdine</item><BR>                                       <item>ketoconazole, itraconazole, clarithromycin</item><BR>                                       <item>other potent CYP3A inhibitors (e.g., nefazodone, telithromycin)</item><BR>                                    </list><BR>                                 </td><BR>                                 <td styleCode="Rrule">150 mg twice daily</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Other concomitant medications, including tipranavir/ritonavir, nevirapine, raltegravir all NRTIs and enfuvirtide </td><BR>                                 <td styleCode="Rrule">300 mg twice daily</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Potent CYP3A inducers (without a potent CYP3A inhibitor) including:<list listType="unordered" styleCode="Disc"><BR>                                       <item>efavirenz</item><BR>                                       <item>rifampin</item><BR>                                       <item>etravirine</item><BR>                                       <item>carbamazepine, phenobarbital, and phenytoin</item><BR>                                    </list><BR>                                 </td><BR>                                 <td styleCode="Rrule">600 mg twice daily</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                     <BR><BR><BR><BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     2.2 Dose Recommendations for Patients with Renal Impairment<BR>                     <BR>                        <BR>                           Table 2 provides dosing recommendations for patients based on renal function and concomitant medications.<BR>                        <BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="100%" ID="table2"><BR>                           <caption>Table 2 Recommended Dosing Regimens Based on  Renal Function </caption><BR>                           <col align="left" width="35%" valign="middle"/><BR>                           <col align="center" width="13%" valign="middle"/><BR>                           <col align="center" width="13%" valign="middle"/><BR>                           <col align="center" width="13%" valign="middle"/><BR>                           <col align="center" width="13%" valign="middle"/><BR>                           <col align="center" width="13%" valign="middle"/><BR>                           <thead><BR>                              <tr styleCode="Botrule"><BR>                                 <th rowspan="3" styleCode="Botrule Lrule Rrule">Concomitant Medications<footnote ID="t2f1">See <linkHtml href="#table1">Table 1</linkHtml> for the list of concomitant medications.</footnote><BR>                                 </th><BR>                                 <th styleCode="Botrule Lrule" align="center" colspan="5">SELZENTRY Dose Based on Renal Function</th><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <th styleCode="Lrule Rrule" align="center">Normal</th><BR>                                 <th styleCode="Lrule">Mild</th><BR>                                 <th styleCode="Lrule">Moderate</th><BR>                                 <th styleCode="Lrule">Severe</th><BR>                                 <th styleCode="Lrule">End Stage Renal Disease (ESRD)</th><BR>                              </tr><BR>                              <tr><BR>                                 <th styleCode="Lrule Rrule" align="center">CrCl  &gt;80 mL/min</th><BR>                                 <th styleCode="Lrule">CrCl &gt;50 and &#8804;80 mL/min</th><BR>                                 <th styleCode="Lrule">CrCl &#8805;30 and &#8804;50 mL/min</th><BR>                                 <th styleCode="Lrule">CrCl &lt;30 mL/min</th><BR>                                 <th styleCode="Lrule">On Regular Hemodialysis</th><BR>                              </tr><BR>                           </thead><BR>                           <tfoot><BR>                              <tr><BR>                                 <td align="left" colspan="6">NR = not recommended</td><BR>                              </tr><BR>                           </tfoot><BR>                           <tbody><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Potent CYP3A inhibitors (with or without a CYP3A inducer)<footnoteRef IDREF="t2f1"/><BR>                                    </content><BR>                                 </td><BR>                                 <td styleCode="Lrule">150 mg twice daily</td><BR>                                 <td styleCode="Lrule">150 mg twice daily</td><BR>                                 <td styleCode="Lrule">150 mg twice daily</td><BR>                                 <td styleCode="Lrule">NR</td><BR>                                 <td styleCode="Lrule">NR</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Other concomitant medications*</content><BR>                                 </td><BR>                                 <td styleCode="Lrule">300 mg twice daily</td><BR>                                 <td styleCode="Lrule">300 mg twice daily</td><BR>                                 <td styleCode="Lrule">300 mg twice daily</td><BR>                                 <td styleCode="Lrule">300 mg twice daily<footnote ID="t2f2">The SELZENTRY dose should be reduced to 150 mg twice daily if there are any symptoms of postural hypotension [see <content styleCode="italics"><BR>                                          <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml><BR>                                       </content>].</footnote><BR>                                 </td><BR>                                 <td styleCode="Lrule">300 mg twice daily<footnoteRef IDREF="t2f2"/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Potent CYP3A inducers (without a potent CYP3A inhibitor)<footnoteRef IDREF="t2f1"/><BR>                                    </content><BR>                                 </td><BR>                                 <td styleCode="Lrule">600 mg twice daily</td><BR>                                 <td styleCode="Lrule">600 mg twice daily</td><BR>                                 <td styleCode="Lrule">600 mg twice daily</td><BR>                                 <td styleCode="Lrule">NR</td><BR>                                 <td styleCode="Lrule">NR</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                     <BR><BR><BR><BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>